8-K ·Filed May 1, 2026
8-K context-dependent: Items 5.02
Actionable Insight • Neutral
Routine compensation disclosure with no trading signal. Monitor next quarterly report for impact on cash flows and dilution from equity awards.
Final — all horizons settled through T+60d
BRTX ▲ +2.11% at T+60d
NEUTRAL call +2.11% · α vs SPY +0.25% · entry $0.2420 → $0.2471
T+1d
0.00%
call 0.00% · α -0.80%
$0.2420
settled 6mo ago
T+5d
-16.86%
call -16.86% · α -19.80%
$0.2012
settled 6mo ago
T+20d
+67.93%
call +67.93% · α +62.29%
$0.4064
settled 5mo ago
T+60d
+2.11%
call +2.11% · α +0.25%
$0.2471
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
BioRestorative Therapies disclosed cash bonuses for its named executive officers for fiscal year 2025, with total compensation increases across all three executives. The filing is a routine compensatory arrangement update with no officer changes or departures.
Key Facts
- On May 1, 2026, the Compensation Committee approved cash bonuses for the year ended December 31, 2025.
- CEO Lance Alstodt total compensation: $2,409,167 (2025) vs $1,314,583 (2024).
- VP R&D Francisco Silva total compensation: $2,322,916 (2025) vs $1,227,083 (2024).
- CFO Robert Kristal total compensation: $801,750 (2025) vs $683,752 (2024).
- Bonuses are discretionary and to be paid in 2026.
Financial Impact
Total executive compensation increased by approximately $1.3 million year-over-year across three officers.
compensation expense
Risk Factors
- Compensation expense may pressure cash reserves given $6M market cap, but this is already disclosed in prior filings.
Market Snapshot
Exchange
Nasdaq
Sector
Services-Misc Health & Allied Services, NEC
Analyst Consensus
88% bullish (8 analysts)
Investment Themes
Healthcare & Medical Devices
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001021771-26-000068 |
| Document: 0001021771-26-000068-index-headers.html | 0001021771-26-000068 |
| Document: 0001021771-26-000068-index.html | 0001021771-26-000068 |
| Document: 0001021771-26-000068.txt | 0001021771-26-000068 |
8 reports for BRTX
75% Hit rate @ T+20 Went positive at some point 4 of 4 best @ T+60▲ +45.25%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $1.75 | awaiting T+20 | — | $1.36 (−22.29%) |
Sep 11, 2026 6w ago | 8-K | $2.67 $1.91 | ▲ +28.46% | ▲ +30.33% | $1.36 (+49.06%) |
Sep 2, 2026 7w ago | Press Release | $0.1437 $2.14 | ▲ +1389.21% | ▲ +1389.67% | $1.36 (+846.42%) |
Aug 25, 2026 8w ago | 8-K | $0.2169 $2.51 | ▼ −1057.22% | ▼ −1057.07% | $1.36 (−527.02%) |
Jun 12, 2026 19w ago | 8-K | $0.3910 $0.3400 | ▲ +13.04% | ▲ +13.04% | $1.36 (−247.83%) |
May 29, 2026 21w ago | 8-K | $0.4064 $0.3760 | ▲ +7.48% | ▲ +6.18% | $1.36 (−234.65%) |
May 1, 2026 25w ago | 8-K | $0.2420 $0.4064 | ▲ +67.93% | ▲ +62.29% | $1.36 (+461.98%) |
Apr 7, 2026 29w ago | Press Release | $0.2507 $0.2420 | ▼ −3.47% | ▼ −13.25% | $1.36 (+442.48%) |
Showing 8 of 8
US Market Status
Market Closed — Opens Wed (17h 17m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers